Another type of test coming out of thegenomicrevolution involves looking at individual genetic mutations that are known to be associated with specific medical consequences.
Thegenomicrevolution is simply providing us with more things to measure, but only a very small fraction of these are medically meaningful and can be turned into new diagnostics.
Schroer's fund, invested largely in pharmaceuticals and biotech, is up 35% so far this year on the strength of some good venture-capital investments and investor excitement over the potential genomicrevolution.